Answers are grounded in this paper and cite their sources.
Randomized trial finds rituximab is not superior to cyclophosphamide in severe ANCA-associated vasculitis, indicating both regimens achieve high sustained-remission rates without safety differences.
A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-based regimen was not associated with reductions in early severe adverse events. (Funded by Cambridge University Hospitals National Health Service Foundation Trust and F. Hoffmann-La Roche; Current Controlled Trials number, ISRCTN28528813.)
No takes yet. Share an insight, caveat, or question.
Jones et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: